Atara Biotherapeutics Provides Update on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics Provides Update on EBVALLO™ (tabelecleucel) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for EBVALLO™…

Read MoreAtara Biotherapeutics Provides Update on EBVALLO™ (tabelecleucel)

Healthcare Empowered: Vim Launches Care Insights for Smarter, Data-Driven Decisions

Healthcare Empowered: Vim Launches Care Insights for Smarter, Data-Driven Decisions Vim, a leader in connected healthcare technology and clinical workflow integration, has announced the launch of Care Insights, a revolutionary solution designed to improve healthcare delivery by embedding real-time, patient-specific…

Read MoreHealthcare Empowered: Vim Launches Care Insights for Smarter, Data-Driven Decisions

Cell Therapy Platform Enhanced: Charles River and Akron Bio Integrate CGMP Materials

Cell Therapy Platform Enhanced: Charles River and Akron Bio Integrate CGMP Materials Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio, a leading supplier of critical materials and services for advanced therapies, have announced a new collaboration to integrate…

Read MoreCell Therapy Platform Enhanced: Charles River and Akron Bio Integrate CGMP Materials

NextGen Healthcare Launches NextGen® Gastro Suite to Enhance GI Care

NextGen Healthcare Launches NextGen® Gastro Suite to Enhance GI Care NextGen Healthcare, a leader in healthcare technology innovation, has introduced the NextGen® Gastro Suite, a new solution designed to integrate gastroenterology-specific workflows into the NextGen® Enterprise EHR (electronic health record).…

Read MoreNextGen Healthcare Launches NextGen® Gastro Suite to Enhance GI Care

Inflammasome Therapeutics Reports Positive 3-Month Data for K8 in Geographic Atrophy

Inflammasome Therapeutics Reports Positive 3-Month Data for K8 in Geographic Atrophy Inflammasome Therapeutics, a clinical-stage biotech company at the forefront of developing dual inflammasome inhibitors for prevalent ophthalmic and neurodegenerative diseases, has announced promising topline results from a clinical trial…

Read MoreInflammasome Therapeutics Reports Positive 3-Month Data for K8 in Geographic Atrophy

Sinaptica Launches Co-Development of SinaptiStim® for Alzheimer’s, Pivotal Trial Set for 2025

Sinaptica Launches Co-Development of SinaptiStim® for Alzheimer’s, Pivotal Trial Set for 2025 Sinaptica Therapeutics, Inc., a clinical-stage company at the forefront of developing personalized neuromodulation treatments for Alzheimer’s and other neurodegenerative diseases, has announced the initiation of co-development for the…

Read MoreSinaptica Launches Co-Development of SinaptiStim® for Alzheimer’s, Pivotal Trial Set for 2025

SurGenTec Gains FDA Clearance for OsteoFlo® HydroFiber™ for Stand-Alone Use

SurGenTec Gains FDA Clearance for OsteoFlo® HydroFiber™ for Stand-Alone Use SurGenTec is excited to announce that its innovative product, OsteoFlo HydroFiber, has received FDA 510(k) clearance, marking a major milestone in the evolution of bone graft technology. This clearance establishes…

Read MoreSurGenTec Gains FDA Clearance for OsteoFlo® HydroFiber™ for Stand-Alone Use

Cancer Research Accelerated: Guardant Health and ConcertAI Launch Data-As-A-Service

Cancer Research Accelerated: Guardant Health and ConcertAI Launch Data-As-A-Service Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, and ConcertAI, a top provider of oncology real-world evidence (RWD) data and AI-driven SaaS technology, have announced a new collaboration. This…

Read MoreCancer Research Accelerated: Guardant Health and ConcertAI Launch Data-As-A-Service